February 21, 2024
Charles River Laboratories International, Inc. today announced a strategic agreement with Wheeler Bio, Inc., an antibody contract development and manufacturing organization (CDMO) focused on preclinical and early clinical supply of recombinant proteins, providing clients access to Wheeler’s Portable CMC® (Chemistry, Manufacturing and Controls) platform. This new alliance provides early-stage biotechnology companies a unique solution to rapidly transition from pre-clinical activities to first-in-human clinical trials. Combining Charles River’s industry-leading experience in antibody discovery services, safety, and analytics with Wheeler’s Portable CMC® platform will accelerate therapeutic discovery to IND submission timelines.
Read MoreJanuary 23, 2024
TARA Mind, a public benefit corporation focused on creating access to safe and effective ketamine-assisted therapy (KAT) as a covered benefit for employees, announced today that the Company has raised $8 million, led by Satori Neuro. Additional investors participating in the oversubscribed round were Echo Investment Capital, Crumpton Ventures, Empath Ventures, and Blake Mykoskie: Founder of TOMS.
Read More